Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
about
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisStatins and Renin Angiotensin System Inhibitors Dose-Dependently Protect Hypertensive Patients against Dialysis RiskRelation of serum lipids and lipoproteins with progression of CKD: The CRIC study.Renal failure (chronic)Association of dyslipidemia with renal outcomes in chronic kidney disease.Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis.Dyslipidemia in chronic kidney disease: managing a high-risk combination.Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study.Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-AnalysisIMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid- lowering component of ALLHAT.Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial.Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.Statins, inflammation and kidney disease.Complications and characteristics of patients referred to a joint diabetes renal clinic in Ireland.Treatment and impact of dyslipidemia in diabetic nephropathy.Statins in chronic kidney disease: cardiovascular risk and kidney function.Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension.Definitions of progression in chronic kidney disease--predictors and relationship to renal replacement therapy in a population cohort with a 6 year follow-up.Effect of Statins on Renal Function in Chronic Kidney Disease Patients
P2860
Q24194514-9848F54C-F2B7-4DA5-A1B9-D80B1AAA914CQ28554193-EC7645F9-EC19-476F-B366-27C96996072EQ33835707-48DF512D-9204-4D19-A8DE-1A2C6F170601Q33910618-5E28598D-182B-4A77-8105-13084DD1EE11Q34580123-9707D9D5-764E-47FF-B8D7-2F8B5363F3F3Q34979484-BF1886ED-6AFF-484E-AB85-285326A250DBQ35014627-03F40622-6FC9-4DE9-9942-F5835587B37FQ35571714-19E103F7-AFC5-4445-B58B-DB84EDB11A7EQ35685253-4D734FB9-0AA4-4C30-B3E6-BB42E7A53D34Q35691372-8E566897-A54A-423C-AF4A-E3628EE621F3Q35856929-1AA269F1-0582-4D28-9DE7-BB1BC8AA470EQ36025075-C1668EAB-DE43-4AE4-8D30-32B9411D45F3Q36365884-ABBEFCED-E1E7-4909-8C51-C5A7174F9F80Q37704388-006A439F-B6B5-4554-A18E-037FB170B6CAQ37883015-8E6E74D2-F121-45DF-B8E1-BD3469964C8FQ37998946-7B32DDAC-67C9-40E5-952B-CF791C847F08Q38160397-73CD48B7-669F-4923-9438-FD5E1B869242Q38176142-0366B848-713F-4FBF-9759-8CDAE5B8CEDDQ38372669-A90A1429-62D9-4E0A-B40D-88511C3C35BEQ38513740-8D364A0C-CE2F-46A2-B59D-3AE59FCE7303Q43274969-6E486C88-9AA9-4C4C-9A35-3759B29F7440Q44608520-BC1EBDF8-565E-4F95-AC97-3CB27B55425AQ58618169-FD0FA104-1D75-42C3-B057-1D4682280D4C
P2860
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Progression of kidney disease ...... t Heart Attack Trial (ALLHAT).
@ast
Progression of kidney disease ...... t Heart Attack Trial (ALLHAT).
@en
type
label
Progression of kidney disease ...... t Heart Attack Trial (ALLHAT).
@ast
Progression of kidney disease ...... t Heart Attack Trial (ALLHAT).
@en
prefLabel
Progression of kidney disease ...... t Heart Attack Trial (ALLHAT).
@ast
Progression of kidney disease ...... t Heart Attack Trial (ALLHAT).
@en
P2093
P2860
P1476
Progression of kidney disease ...... t Heart Attack Trial (ALLHAT).
@en
P2093
ALLHAT Collaborative Research Group
Barry R Davis
Carol Stanford
Charles Baimbridge
Clive Rosendorff
Gail T Louis
Jan N Basile
Joshua Barzilay
Mahboob Rahman
P2860
P304
P356
10.1053/J.AJKD.2008.05.027
P577
2008-08-03T00:00:00Z